Androgen deprivation therapy (ADT) has been the cornerstone of treatment for men with hormone-sensitive prostate cancer, but most men with advanced disease stop responding to conventional ADT. After the approval of docetaxel in 2004, few advances were made in treatment for castrate-resistant prostate cancer (CRPC)—until 2010. Then, five agents were approved in quick succession. These comprise a taxane, cabazitaxel; an immunotherapy, sipuleucel-T; two androgen receptor signaling inhibitors, abiraterone and enzalutamide; and radium-223, a radiopharmaceutical. Treatment for nonmetastatic CRPC has also evolved with the approvals of both apalutamide and enzalutamide for this indication. This activity discusses current treatment strategies and newer agents for metastatic and nonmetastatic CRPC.
eNewsletter with interactive benchmarking
After completing this activity, participants should be better able to:
- Discuss current treatment strategies and investigational agents for nonmetastatic CRPC
- Review clinical trial data for the efficacy of new and emerging agents for metastatic CRPC
- Identify strategies for optimizing patient adherence to prostate cancer therapy, including strategies for managing adverse events
Oncology nurse practitioners, physician assistants, and nurses
In support of improving patient care, Continuing Education Alliance is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Nursing contact hours: 1.00, which includes 1.00 hours of pharmacology credit
Nurse planner: Beth Eaby-Sandy, MSN, CRNP, OCN, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania
This program has been reviewed and is approved for a maximum of 1.0 AAPA Category 1 CME credits by the AAPA Review Panel. Approval is valid for one year from the issue date of August 15, 2018. Participants may submit the post-test at any time during that period.
This program was planned in accordance with AAPA CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.
This program was cosupported by educational grants from Astellas and Pfizer; Bristol-Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc; Lilly USA, LLC; Merck & Co., Inc.; Sanofi Genzyme; and Taiho Oncology, Inc. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
This activity is supported by an educational grant from Astellas and Pfizer.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Continuing Education Alliance, Practicing Clinicians Exchange, the AAPA, or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Continuing Education Alliance are required to disclose to the audience any significant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Geynisman: consultant/advisor: Exelixis, Novartis, Pfizer; grant/research support: Genentech, Merck, Millennium, Pfizer.
The Planning Committee for this activity included Ruth Cohen, Warren Beckman, Craig Borders, Leslie Burgess, Kathleen Crowley, Jacqueline Egan, Margaret Inman, Devera Pine, Marie Recine, and Stef Stendardo of Continuing Education Alliance; Lee Schwartzberg, MD, of the University of Tennessee Health Science Center; Beth Eaby-Sandy, MSN, CRNP, OCN, of the University of Pennsylvania; and Jessica Garner, MMS, PA-C, of the University of the Pacific. The members of the Planning Committee have no relevant relationships to disclose, except for: Ms Eaby-Sandy: consultant: AbbVie; speakers bureau: AstraZeneca, Helsinn, Merck, Takeda; Dr Schwartzberg: consultant: Pfizer.
Participants wishing to earn CE/CME credit must:
- Read the eNewsletter in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form online
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete this activity is 1.00 hours.
Release date: August 15, 2018 Expiration date: August 15, 2019
© 2019 Practicing Clinicians Exchange. All Rights Reserved. OPCE92818-7E